Navigation Links
Acne Scars Significantly Improved by a Combination Treatment of Photodynamic Therapy and Percutaneous Collagen Induction

PHOENIX, Oct. 4 /PRNewswire/ -- The appearance of facial acne scars showed greater improvement with a combination treatment of photodynamic therapy (PDT) and percutaneous collagen induction (PCI or medical needling) with the ENVIRON® Surgical Roll-CIT(TM) compared to PDT alone.

The results of the pilot split-face comparison were presented by Hilton Kaplan, MD PhD, Medical Advisor for ENVIRON® distributor DermoGenesis, at the 2009 Joint Annual Meeting of the American Society of Dermatologic Surgery (ASDS) and American Society of Cosmetic Dermatology & Aesthetic Surgery (ASCDAS).

"Facial acne scars are disfiguring and medically challenging to treat," noted Julie Kenner, MD PhD, the study's lead author and a dermatologist in Kailua, Hawaii. "Combining PDT and medical needling offers an effective new treatment for acne scarring that is suitable for all skin types and regions because it does not strip or remove the epidermis."

PDT uses photosensitive chemicals activated by light to treat targeted areas of acne scarring. Medical needling with the ENVIRON® Surgical Roll-CIT(TM) improves scarring by creating micro-clefts in the skin, which initiates a platelet-driven healing cascade that results in regenerative forms of collagen and elastin.

After three treatments, the side treated with PDT and PCI showed an average increase in Type I collagen and epidermal thickness that was, respectively, 5.46 and 10.5 times greater than the side treated with PDT alone. Results were verified by comparing clinical photographs and histological samples obtained prior to and after the treatments.

Four subjects with facial acne scarring and Fitzpatrick skin types II to IV were included in the pilot study. During the treatment, medical needling was performed on the right cheek of each subject. Then, 5-aminolevinic acid (ALA) was applied to both cheeks and activated by IPL (400-700nm). Sunscreen and ENVIRON® topical products containing fat forms of vitamins A and C were used daily throughout.

For more information, please visit or email

About ENVIRON and DermoGenesis

ENVIRON offers a complete and synergistic system of skin care products and medical-needling devices that is available only through medical doctors and ENVIRON-trained professionals. DermoGenesis is a distributor of ENVIRON in the United States.

SOURCE DermoGenesis

SOURCE DermoGenesis
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Isolagen, Inc. Reports Positive Top-line Results from Phase II/III Study of Isolagen Therapy(TM) to Treat Moderate to Severe Acne Scars: Study Meets All Primary Efficacy Endpoints and is Statistically Significant
2. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
3. DEFLUX(R) Significantly Reduces Urinary Tract Infections in Children With Vesicoureteral Reflux
4. Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS)
5. Nexavar Significantly Improved Overall Survival in Phase 3 Asia-Pacific Liver Cancer Trial
6. Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia
7. New Data Reveal Topical Divigel(R) (estradiol gel) 0.1% Significantly Reduces Frequency and Severity of Hot Flashes
8. Promising Phase 3 Trial Results Show Novel Biologic Therapy Ustekinumab (CNTO 1275) Significantly Improved Psoriasis
9. INVEGA(TM) Significantly Reduced Symptoms of Schizophrenia Compared to SEROQUEL(R) in Acutely Ill, Hospitalized Patients
10. New Data Published in Neurology Show Once-Daily Lamictal XR Significantly Reduced Partial Seizures in Patients with Epilepsy
11. Anesiva Announces Pivotal Phase 3 Trial of Zingo(TM) Meets Primary Endpoint and Significantly Reduces Venous Access Pain in Adults
Post Your Comments:
(Date:6/23/2016)... and BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment of Astellas ... Brasil as the company,s second affiliate in Latin America . ... ... of Astellas Farma Colombia ... ...
(Date:6/23/2016)... The vast majority of dialysis patients currently ... are usually 3 times a week, with treatment times ... time, equipment preparation and wait time.  This regimen can ... patients who are elderly and frail.  Many elderly dialysis ... centers for some duration of time. Residents ...
(Date:6/23/2016)... YORK , June 23, 2016 ... waters, but it continues to present great opportunities to ... companies for today: Intrexon Corp. (NYSE: XON ... Arena Pharmaceuticals Inc. (NASDAQ: ARNA ), and ... more about these stocks and receive your complimentary trade ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now ... of Final Cut Pro X," said Christina Austin - CEO of Pixel Film Studios. ... Final Cut Pro X users can now reveal the media of their split ...
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating ... many ways they remain in the eye of the beholder, according to experts who ... of The American Journal of Managed Care. For the full issue, click here ...
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... ... fertility once they have been diagnosed with endometriosis. These women need a treatment ... also require a comprehensive approach that can help for preservation of fertility and ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , ... Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. , ... our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article ... are unfamiliar with. The article goes on to state that individuals are now more ... these less common operations such as calf and cheek reduction. The Los Angeles area ...
Breaking Medicine News(10 mins):